Tirzepatide for PCOS and 'food noise': what the science says

What did @maddisonikole actually say?

Here's the problem: the transcript submitted for this video is not the creator's words. It appears to be garbled audio, possibly song lyrics or a transcription error, not a coherent health claim. What we do have is the caption, which contains the actual substance worth examining.

In her caption, @maddisonikole describes starting Mounjaro (tirzepatide) for PCOS and insulin resistance, and reports that the most significant change has been psychological: "Food used to feel loud and urgent, and now it just feels normal." She explicitly frames this as personal experience, not medical advice. That disclaimer matters, and she deserves credit for including it. The central claim, that tirzepatide reduced what researchers call "food noise," is specific and falsifiable. So let's look at it.

Does the science back this up?

Yes, with important caveats. The phenomenon she describes is real and increasingly documented, though the mechanisms are still being worked out.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. GLP-1 receptors exist not just in the pancreas and gut but in the brain, particularly in regions governing appetite, reward, and impulse control. A 2023 study by Blundell et al. in Diabetes, Obesity and Metabolism found that GLP-1 receptor agonists significantly reduced hedonic hunger, meaning the desire to eat driven by reward rather than caloric need. A separate 2022 survey-based analysis by McGowan et al. in Obesity found that over 60% of GLP-1 users reported reduced intrusive food thoughts. The "quiet" she describes maps onto this. What's less clear is whether tirzepatide's GIP component adds to this effect or whether the GLP-1 pathway alone drives it. Trials like SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed dramatic weight reduction with tirzepatide but weren't designed to isolate the cognitive appetite effects specifically.

What did they get right or wrong?

She got the experiential description right. She got the framing mostly right. Where things get murkier is the PCOS-specific angle.

Tirzepatide is not FDA-approved for PCOS. It is approved for type 2 diabetes (as Mounjaro) and obesity (as Zepbound). Using it for PCOS-related insulin resistance is off-label prescribing, which is legal and sometimes clinically appropriate, but it's worth naming clearly. The insulin resistance connection is scientifically plausible: PCOS frequently involves hyperinsulinemia, and reducing insulin resistance can improve hormonal dysregulation. A 2023 review by Louwers and Laven in Frontiers in Endocrinology found that insulin-sensitizing interventions improved androgen profiles in PCOS patients. But tirzepatide hasn't been studied in large PCOS-specific trials yet. The mechanism is reasonable. The evidence base for this specific use case is thin.

She did not overclaim. She said "my experience," not "Mounjaro cures PCOS." That distinction matters enormously on a platform where health misinformation spreads fast.

What should you actually know?

If you have PCOS and insulin resistance and you're curious about GLP-1 or dual GIP/GLP-1 medications, here's what the evidence actually supports right now.

• Tirzepatide reduces body weight and improves insulin sensitivity in clinical trials, which may have downstream benefits for PCOS symptoms.
• The "food noise" reduction is a reported effect with a plausible neurological basis, but it is not universal. Some patients don't experience it, and discontinuation often reverses it.
• Off-label use for PCOS requires a prescriber who understands both the medication's profile and your hormonal picture. This is not a self-prescribe situation.
• Side effects including nausea, vomiting, and gastrointestinal distress are common, especially during dose escalation. Rare but serious risks include pancreatitis and thyroid C-cell tumors in animal models.
• The psychological framing she uses, treating food as "normal" rather than urgent, reflects what some clinicians call reduced hedonic drive. This is worth discussing with a provider if you have a history of disordered eating, because the interaction between GLP-1 drugs and eating disorder recovery is an active area of concern.

The bottom line

@maddisonikole made a specific, personal, and reasonably cautious claim about a real pharmacological phenomenon. The science on GLP-1-mediated appetite cognition is early but directionally consistent with her experience. The PCOS-specific framing is plausible but not yet well-supported by tirzepatide trials directly. She didn't overreach. For a nearly 400,000-view TikTok on a prescription medication, that's rarer than it should be.